<DOC>
	<DOCNO>NCT00867087</DOCNO>
	<brief_summary>The purpose study evaluate inotuzumab ozogamicin combination rituximab prior autologous stem cell transplant ( aSCT ) patient relapsed/refractory diffuse large B-cell Non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study Evaluating Inotuzumab Ozogamicin ( CMC-544 ) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>CD20/CD22positive diffuse large Bcell NHL relapse 1 2 prior therapy ; one prior therapy must include anthracyclines one must include rituximab combination chemotherapy Relapsed/disease progression within 12 month start prior therapy and/or secondary International Prognostic Index ( sIPI ) score great 1 Eligible autologous stem cell transplant ( aSCT ) Prior allogeneic hematopoietic stem cell transplant Within 6 month prior test article : autologous transplant , treatment antiCD22 antibody , radioimmunotherapy Venoocclusive disease sinusoidal obstruction syndrome , chronic liver disease , systemic vasculitides , current chronic hepatitis B C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Diffuse large b-cell lymphoma</keyword>
	<keyword>inotuzumab ozogamicin</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>